News headlines about MedAssets (NASDAQ:MDAS) have trended positive on Saturday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. MedAssets earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave media stories about the technology company an impact score of 46.4982931817151 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

MedAssets (NASDAQ:MDAS) remained flat at $$31.35 during midday trading on Friday. MedAssets has a fifty-two week low of $17.00 and a fifty-two week high of $31.35.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at

MedAssets Company Profile

MedAssets, Inc (MedAssets) provides technology-enabled products and services to healthcare organizations, including hospitals, health systems, non-acute healthcare providers, payers, other service providers and product manufacturers. The Company operates its business through two business segments: Spend and Clinical Resource Management (SCM) and Revenue Cycle Management (RCM).

Insider Buying and Selling by Quarter for MedAssets (NASDAQ:MDAS)

Receive News & Ratings for MedAssets Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedAssets and related companies with's FREE daily email newsletter.